Loading…
Lobbying Income
$296.8M
Filings
6,187
Unique Clients
98
Active Period
1999–2026
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Biosimilar Red Tape Elimination Act
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.
Client expense: — · Firm income: $340,000
Matched citations: H.R. 5526
Skinny Labels, Big Savings Act
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.
Client expense: — · Firm income: $340,000
Matched citations: H.R. 6485
Skinny Labels, Big Savings Act
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
Medication Affordability and Patent Integrity Act (S. 2658); Biopharmaceutical policy issues; Skinny Labels, Big Savings Act (S. 43/H.R. 6485).
Client expense: — · Firm income: $340,000
Matched citations: H.R. 6485
CLEAR LABELS Act
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.
Client expense: — · Firm income: $340,000
Matched citations: H.R.8269
Expedited Access to Biosimilars Act
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.
Client expense: — · Firm income: $340,000
Matched citations: H.R.9661
Expedited Access to Biosimilars Act
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.
Client expense: — · Firm income: $340,000
Matched citations: S. 1414
Biosimilar Red Tape Elimination Act
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.
Client expense: — · Firm income: $340,000
Matched citations: S. 1954
Medication Affordability and Patent Integrity Act
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.
Client expense: — · Firm income: $340,000
Matched citations: S. 2658
Medication Affordability and Patent Integrity Act
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
Medication Affordability and Patent Integrity Act (S. 2658); Biopharmaceutical policy issues; Skinny Labels, Big Savings Act (S. 43/H.R. 6485).
Client expense: — · Firm income: $340,000
Matched citations: S. 2658
CLEAR LABELS Act
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.
Client expense: — · Firm income: $340,000
Matched citations: S.3788
Skinny Labels, Big Savings Act
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.
Client expense: — · Firm income: $340,000
Matched citations: S. 43
Skinny Labels, Big Savings Act
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
Medication Affordability and Patent Integrity Act (S. 2658); Biopharmaceutical policy issues; Skinny Labels, Big Savings Act (S. 43/H.R. 6485).
Client expense: — · Firm income: $340,000
Matched citations: S. 43
National Defense Authorization Act for Fiscal Year 2027
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.
Client expense: — · Firm income: $340,000
Matched citations: S. 4784
RESTORE Patent Rights Act of 2025
2026 · third_quarter · Client: QUALCOMM INCORPORATED
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
Client expense: — · Firm income: $610,000
Matched citations: H.R. 1574
Patent Eligibility Restoration Act of 2025
2026 · third_quarter · Client: QUALCOMM INCORPORATED
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
Client expense: — · Firm income: $610,000
Matched citations: H.R. 3152
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
Client expense: — · Firm income: $610,000
Matched citations: H.R. 3160
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
Client expense: — · Firm income: $610,000
Matched citations: H.R. 3539
Patent Eligibility Restoration Act of 2025
2026 · third_quarter · Client: QUALCOMM INCORPORATED
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
Client expense: — · Firm income: $610,000
Matched citations: S. 1546
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
Client expense: — · Firm income: $610,000
Matched citations: S. 1553
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
Client expense: — · Firm income: $610,000
Matched citations: S. 1833
RESTORE Patent Rights Act of 2025
2026 · third_quarter · Client: QUALCOMM INCORPORATED
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
Client expense: — · Firm income: $610,000
Matched citations: S. 708
Semiconductor Superiority Act
2026 · third_quarter · Client: SIERRA SPACE CORPORATION
Tax policies related to space flight and orbital technologies; Semiconductor Superiority Act (H.R. 8959, S.4750).
Client expense: — · Firm income: $60,000
Matched citations: H.R. 8959
Semiconductor Superiority Act
2026 · third_quarter · Client: SIERRA SPACE CORPORATION
Tax policies related to space flight and orbital technologies; Semiconductor Superiority Act (H.R. 8959, S.4750).
Client expense: — · Firm income: $60,000
Matched citations: S.4750
Issues related to restaurants and restaurant franchising, including franchising business model and trade; The American Franchise Act (H.R. 5267).
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5267
Secure Family Futures Act of 2025
2026 · third_quarter · Client: JOHN HANCOCK LIFE INSURANCE COMPANY (USA) (FKA JOHN HANCOCK FIN. SERVICES, INC.)
Retirement; long term care insurance; support H.R. 2547, Secure Family Futures Act; expand HSA eligibility for life-prolonging programs; encouraging OPM to save money by consolidating federal benefit programs administration.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 2547
Source: Senate LDA